LIM Domain Only 1: An Oncogenic Transcription Cofactor Contributing to the Tumorigenesis of Multiple Cancer Types
The LIM domain only 1 (LMO1) gene, a member of the LMO gene family, encodes a group of transcriptional cofactors that play a crucial role in regulating gene transcription by acting as key connectors or scaffolds in transcription complexes. LMO1, along with other LMO family members, has been increasingly recognized for its unique biological features, including tissue-specific expression patterns, interacting proteins, and transcriptional targets. This article provides a comprehensive review of the current findings on the role of LMO1 in tumorigenesis, its oncogenic mechanisms, and its aberrant activation in various cancers.
Background and Structure of LMO1 LMO1, located on human chromosome 11p15.4, is also known as T-cell translocation gene 1 (TTG-1) or rhombotin. The LMO gene family consists of four members: LMO1, LMO2, LMO3, and LMO4. These proteins share a common LIM domain, a cysteine-rich zinc-binding motif, which is essential for their function as transcription cofactors. Despite their structural similarity, each LMO protein has unique biological features, such as tissue-specific expression patterns, interacting proteins, and gene targets, which contribute to their diverse and complex functions in tumorigenesis.
LMO1 was first identified in T-cell acute lymphoblastic leukemia (T-ALL) as a gene disrupted by a t(11;14)(p15;q11) genetic translocation event. Its oncogenic function was initially characterized in T-ALL and neuroblastoma. Over time, it has been recognized that LMO1 plays an essential role in normal development and that its aberrant expression contributes to various human diseases, including multiple types of cancers.
LMO1 in Blood Cancers LMO1’s role in blood cancers was first characterized in T-ALL, an aggressive malignant blood cancer. Studies have shown that LMO1 forms an interplay network with multiple key oncogenic players in T-ALL, including TAL1/SCL, LYL1, LDB1, OLIG2, and NOTCH1, driving the process of oncogenesis. LMO1 has also been found to contribute to the oncogenesis of other blood cancers, such as precursor T-cell lymphoblastic lymphoma/leukemia (pre-TLBL), indicating its universal oncogenic role in blood cancers.
LMO1 gene alterations in T-ALL were first identified in a patient with T-ALL and the T-cell line RPMI8420, where a chromosomal translocation event resulted in the pathogenic activation of LMO1. Single-nucleotide polymorphisms (SNPs) in LMO1 have also been associated with the risk of developing acute lymphoblastic leukemia (ALL). For example, the SNP rs442264 in the LMO1 locus was significantly associated with the risk of developing precursor-B-cell leukemia.
In vivo and in vitro studies using transgenic mouse models have further characterized the carcinogenic role of LMO1 in T-ALL. Overexpression of LMO1 in transgenic mice led to the development of immature, aggressive T-cell leukemia/lymphomas, with tumor incidence proportional to the level of LMO1 expression. Additionally, the TAL1/SCL and LMO1 double transgenic mouse model demonstrated that these genes have synergistic effects on T-ALL occurrence.
The mechanism of action of LMO1 in blood cancers involves its interaction with various transcription factors. LMO1 regulates target gene transcription by forming complexes with other transcriptional factors, such as TAL1/SCL, LYL1, and NOTCH1. These interactions are mediated by the binding of the LIM domains in LMO1 to the bHLH sequences in the bHLH proteins. The oncogenic role of the interplay between TAL1/SCL and LMO1 has been verified in vivo, where mice with transgenic co-overexpression of LMO1 and TAL1/SCL developed aggressive T-cell leukemia/lymphoma with high penetrance.
LMO1 and Neuroblastoma Neuroblastoma, a childhood cancer of the sympathetic nervous system, has been strongly associated with genetic variations in LMO1. Genome-wide association studies (GWAS) have identified several SNPs in LMO1 that are associated with the risk of developing neuroblastoma. For example, the SNP rs110419 in the LMO1 locus was found to be strongly related to a reduced risk of neuroblastoma development. Other SNPs, such as rs4758051 and rs10840002, have also been associated with decreased neuroblastoma risk in various populations.
The oncogenic mechanism of LMO1 in neuroblastoma involves its interaction with MYCN, a well-known oncogene in neuroblastoma. Transgenic coexpression of MYCN and LMO1 in zebrafish resulted in widespread tumor masses, indicating that LMO1 has a strong synergistic impact in potentiating the oncogenic function of MYCN. RNA sequencing studies have identified multiple downstream targets of LMO1, including genes encoding matrisome-associated proteins, ECM regulators, and integrins, which contribute to metastasis in neuroblastoma by promoting tumor cell invasion and migration.
LMO1 also interacts with other transcription factors, such as GATA3 and ASCL1, to regulate gene expression in neuroblastoma cells. The LMO1-GATA3 complex occupies the transcription regulatory element of ASCL1, a bHLH transcription factor, and coordinately regulates its expression. Additionally, LMO1 has been found to directly upregulate the expression of the receptor tyrosine kinase RET, which is implicated in neuroblastoma tumorigenesis.
Mechanisms Regulating LMO1 Expression and Function Genetic variations, such as SNPs and gene copy number alterations, are common mechanisms that result in the gain-of-function of LMO1 in cancers. For example, increased copy number of the LMO1 gene locus has been associated with more advanced disease and poor survival in neuroblastoma. Transcriptional regulation of LMO1 expression involves the interaction of LMO1 with various transcription factors, such as TAL1/SCL and GATA3, which bind to enhancer regions in the LMO1 promoter to drive its expression.
Epigenetic modulation of gene expression also plays a role in regulating LMO1 expression. For example, the let-7 microRNA family has been found to indirectly repress LMO1 expression by inhibiting TGF-bI/TGFbRI signaling. Disruption of this pathway can lead to the aberrant overexpression of both LMO1 and MYCN in neuroblastoma cells.
LMO1 in Other Cancer Types LMO1 has been increasingly recognized for its oncogenic role in several other cancer types, including prostate cancer, gastric cancer, lung cancer, and colorectal cancer. In prostate cancer, LMO1 acts as an androgen receptor (AR) coactivator, upregulating the expression of P21 and prostate-specific antigen (PSA), which are implicated in cancer progression. In gastric cancer, LMO1 regulates the expression of Bcl-2 and Bax, which are involved in the mitochondrial apoptosis pathway.
In lung cancer and colorectal cancer, LMO1 has been associated with reduced responsiveness to the EGFR tyrosine kinase inhibitor cetuximab. LMO1 expression is correlated with elevated AKT phosphorylation, which is required for its oncogenic effects. Additionally, LMO1 has been found to be expressed at significantly higher levels in small cell lung cancer cells than in non-small lung cancer cells, and its expression level is correlated with neuroendocrine differentiation of lung cancer.
Conclusion LMO1 is a critical oncogene involved in the tumorigenesis of multiple cancer types, including T-ALL, neuroblastoma, prostate cancer, gastric cancer, lung cancer, and colorectal cancer. Its oncogenic function is mediated through its interaction with various transcription factors and downstream targets, which regulate key oncogenic processes such as cell proliferation, differentiation, and metastasis. Understanding the mechanisms of LMO1’s oncogenic action and the regulatory pathways that control its expression is essential for developing targeted therapies and diagnostic tools for cancer patients. Further investigations into the LMO1 interactome, transcriptome, and epigenetic regulation will provide valuable insights into its role in cancer and facilitate the translation of laboratory findings to clinical applications.
doi.org/10.1097/CM9.0000000000001487
Was this helpful?
0 / 0